{"groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"FG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"253"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"31"}],"type":"Study Terminated By Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Non-Compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Progression Of Disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"310"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"310"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The analysis included data up to cutoff date 28 February 2023.","recruitmentDetails":"The study is considered \"Completed\" because the planned study activities and analyses have been performed."}